Lucid Diagnostics Inc. (LUCD) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lucid Diagnostics Inc. (LUCD:NASDAQ), powered by AI.

Current Price
$1.02
P/E Ratio
-2.9
Market Cap
167M
Sector
Healthcare
What is the Lucid Diagnostics Inc. stock price forecast?

Lucid Diagnostics Inc. is currently trading at $1.02. View real-time AI analysis on Alpha Lenz.

What is Lucid Diagnostics Inc. insider trading activity?

View the latest insider trading data for Lucid Diagnostics Inc. on Alpha Lenz.

What is Lucid Diagnostics Inc.'s P/E ratio?

Lucid Diagnostics Inc.'s P/E ratio is -2.9.

Lucid Diagnostics Inc.

NASDAQ · LUCD
$1.02+0.02(+2.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Lucid Diagnostics Inc.'s future dividend policy...
Alpha Chat Insight

Lucid Diagnostics Inc. trades at a P/E of -2.9 (undervalued) with modest ROE of -710.6%. 3Y revenue CAGR of 132.0% highlights clear growth momentum.

Ask for details

Company Overview

Lucid Diagnostics Inc. is a medical technology company focusing on the early detection of esophageal precancer and cancer. Their key product line, EsoCheck, is an innovative diagnostic tool designed to aid in the identification of esophageal conditions such as Barrett's Esophagus. This offering is particularly significant as it provides a less invasive, more efficient alternative to traditional diagnostic methods like endoscopy. Operating primarily in the healthcare sector, Lucid Diagnostics aims to enhance early diagnosis rates, potentially improving patient outcomes by enabling earlier intervention. The company plays a crucial role in the early detection landscape, striving to increase awareness and availability of non-invasive diagnostic options. As a part of the broader MedTech industry, Lucid Diagnostics is aligned with the ongoing trend towards preventative healthcare solutions, positioning itself as a key player in improving patient care through technological innovation.

CEODr. Lishan Aklog M.D.
SectorHealthcare
IndustryMedical Devices
Employees72

Company Statistics

FY 2025

Profile

$167.40MMarket Cap
$4.71MRevenue
0.00Shares Out
72Employees

Margins

-41.73%Gross
-1213.68%EBITDA
-1054.82%Operating
-1232.68%Pre-Tax
-1232.68%Net

Valuation

-2.89P/E
15.31P/B
35.57EV/Sales
-2.78EV/EBITDA
-3.59P/FCF

Growth (CAGR)

131.97%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-163.04%ROA
-710.60%ROE
-162.98%ROIC

Financial Health

$34.70MCash & Cash Equivalents
$-5.20MNet Debt
269.83%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lucid Diagnostics Inc. (ticker: LUCD) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 72 employees. Market cap is $167M.

The current price is $1.02 with a P/E ratio of -2.89x and P/B of 15.31x.

ROE is -710.60% and operating margin is -1054.82%. Annual revenue is $5M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lucid Diagnostics Inc. (LUCD) Stock Forecast 2026 $1.02 — Price, Financials & Analyst Targets | Alpha Lenz